PL2454364T3 - Produkcja wirusa polio o wysokim mianie do produkcji szczepionki - Google Patents

Produkcja wirusa polio o wysokim mianie do produkcji szczepionki

Info

Publication number
PL2454364T3
PL2454364T3 PL10729895T PL10729895T PL2454364T3 PL 2454364 T3 PL2454364 T3 PL 2454364T3 PL 10729895 T PL10729895 T PL 10729895T PL 10729895 T PL10729895 T PL 10729895T PL 2454364 T3 PL2454364 T3 PL 2454364T3
Authority
PL
Poland
Prior art keywords
production
high titers
polio virus
vaccine
vaccine production
Prior art date
Application number
PL10729895T
Other languages
English (en)
Inventor
John Alfred Lewis
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PL2454364T3 publication Critical patent/PL2454364T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10729895T 2009-07-16 2010-07-08 Produkcja wirusa polio o wysokim mianie do produkcji szczepionki PL2454364T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
EP09165620 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production
EP10729895.2A EP2454364B1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Publications (1)

Publication Number Publication Date
PL2454364T3 true PL2454364T3 (pl) 2014-09-30

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10729895T PL2454364T3 (pl) 2009-07-16 2010-07-08 Produkcja wirusa polio o wysokim mianie do produkcji szczepionki

Country Status (32)

Country Link
US (4) US8546123B2 (pl)
EP (1) EP2454364B1 (pl)
JP (1) JP5845178B2 (pl)
KR (1) KR101548790B1 (pl)
CN (1) CN102482647B (pl)
AP (1) AP3140A (pl)
AR (1) AR077314A1 (pl)
AU (1) AU2010272685B2 (pl)
BR (1) BR112012000942B8 (pl)
CA (1) CA2763091C (pl)
CO (1) CO6491042A2 (pl)
CU (1) CU20120006A7 (pl)
DK (1) DK2454364T3 (pl)
EA (1) EA020563B1 (pl)
ES (1) ES2484093T3 (pl)
HR (1) HRP20140597T1 (pl)
IL (1) IL217465A (pl)
MA (1) MA33429B1 (pl)
MX (1) MX2011012648A (pl)
MY (1) MY183385A (pl)
NZ (1) NZ596880A (pl)
PE (1) PE20120571A1 (pl)
PL (1) PL2454364T3 (pl)
PT (1) PT2454364E (pl)
RS (1) RS53377B (pl)
SG (1) SG177655A1 (pl)
SI (1) SI2454364T1 (pl)
SM (1) SMT201400079B (pl)
TN (1) TN2011000628A1 (pl)
TW (1) TWI477606B (pl)
WO (1) WO2011006823A1 (pl)
ZA (1) ZA201108271B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
BR112015018493A2 (pt) 2013-02-05 2017-08-22 Univ Georgia Linhagens celulares para produção de vírus e métodos de uso
BR112015021523A8 (pt) 2013-03-08 2021-06-29 Crucell Holland Bv composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
WO2014142433A1 (ko) 2013-03-13 2014-09-18 고려대학교산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
RS57864B1 (sr) 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
JP6591461B2 (ja) 2014-06-17 2019-10-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 低温適応性ウイルス弱毒化（ｃａｖａ）および新規の弱毒化ポリオウイルス株
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
DK3172317T3 (da) * 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
EP3749757A4 (en) * 2018-02-07 2021-11-24 Bharat Biotech International Limited PROCESS FOR PURIFICATION AND INACTIVATION OF ENTERVIRUSES AND VACCINE COMPOSITIONS OBTAINED THEREOF
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
EP3969046A1 (en) 2019-05-16 2022-03-23 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
EP1553983A2 (en) * 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
PL1720972T3 (pl) 2004-03-05 2014-06-30 Dpx Holdings Bv Proces hodowli komórek poprzez ciągłą perfuzję i zmienny przepływ styczny
RS20070078A (sr) 2004-08-27 2008-11-28 Panacea Biotec Ltd., Inaktivirana vakcina protiv poliomijelitisa nastala iz sabinovog soja polio virusa
BRPI0518146A (pt) * 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
WO2008059041A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
HRP20140597T1 (hr) 2009-07-16 2014-09-12 Crucell Holland B.V. Proizvodnja polio virusa u visokim titrima za proizvodnju cjepiva
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
TWI477606B (zh) 2015-03-21
NZ596880A (en) 2013-10-25
JP5845178B2 (ja) 2016-01-20
CN102482647A (zh) 2012-05-30
US20110027317A1 (en) 2011-02-03
CU20120006A7 (es) 2012-10-15
KR20120033334A (ko) 2012-04-06
EP2454364B1 (en) 2014-04-23
AP3140A (en) 2015-02-28
US9022240B2 (en) 2015-05-05
BR112012000942A2 (pt) 2016-03-15
IL217465A0 (en) 2012-02-29
US20130273106A1 (en) 2013-10-17
BR112012000942B8 (pt) 2021-05-25
SG177655A1 (en) 2012-02-28
WO2011006823A1 (en) 2011-01-20
HRP20140597T1 (hr) 2014-09-12
DK2454364T3 (da) 2014-07-21
AU2010272685A1 (en) 2011-12-08
MX2011012648A (es) 2012-01-12
PE20120571A1 (es) 2012-06-06
SI2454364T1 (sl) 2014-08-29
US8546123B2 (en) 2013-10-01
AR077314A1 (es) 2011-08-17
HK1164922A1 (en) 2012-09-28
RS53377B (sr) 2014-10-31
AU2010272685B2 (en) 2015-02-26
CO6491042A2 (es) 2012-07-31
AP2012006075A0 (en) 2012-02-29
CN102482647B (zh) 2015-12-16
MY183385A (en) 2021-02-18
US20130052224A1 (en) 2013-02-28
US20140242670A1 (en) 2014-08-28
BR112012000942B1 (pt) 2020-10-27
MA33429B1 (fr) 2012-07-03
SMT201400079B (it) 2014-09-08
JP2012532616A (ja) 2012-12-20
IL217465A (en) 2016-05-31
ES2484093T3 (es) 2014-08-11
CA2763091C (en) 2019-07-23
EP2454364A1 (en) 2012-05-23
KR101548790B1 (ko) 2015-08-31
TN2011000628A1 (en) 2013-05-24
EA201270173A1 (ru) 2012-06-29
TW201118173A (en) 2011-06-01
PT2454364E (pt) 2014-07-04
EA020563B1 (ru) 2014-12-30
ZA201108271B (en) 2012-07-25
CA2763091A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
AP3140A (en) Production of polio virus at high titers for vaccine production
ZA201202836B (en) Method of preparing plant-derived vlps
HUS1700002I1 (hu) Hepatitis C vírus replikációjának inhibitorai
ZA201202758B (en) Stabilising excipient for inactivated whole-virus vaccines
SI2634191T1 (sl) Postopek za pripravo derivatov tienopirimidindiona
IL219517A0 (en) Hepatitis c virus inhibitors
ZA201101645B (en) Process for prodcution of vaccines
GB0918679D0 (en) Influenza vaccine
EP2488185A4 (en) INFECTIOUS TORQUE TENO VIRUS CLONE
GB2467215B (en) Burkholderia components vaccine
ZA201008125B (en) Inactivated live-attenuated bluetongue virus vaccine
GB0714489D0 (en) Process for preparing viral vaccine
ZA201203862B (en) Dna vaccine against virus of yellow fever
GB0920319D0 (en) HPV vaccine
GB0903910D0 (en) Vaccine production